BioNTech SE (BNTX)
88.17
-0.39
(-0.44%)
USD |
NASDAQ |
Apr 24, 16:00
88.17
0.00 (0.00%)
After-Hours: 16:45
BioNTech Cash from Investing (TTM): -7.529B for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -7.529B |
| September 30, 2023 | -4.801B |
| June 30, 2023 | -3.561B |
| March 31, 2023 | -1.150B |
| December 31, 2022 | -37.23M |
| September 30, 2022 | 6.505M |
| June 30, 2022 | -377.16M |
| March 31, 2022 | -313.20M |
| December 31, 2021 | -669.80M |
| Date | Value |
|---|---|
| September 30, 2021 | -662.42M |
| June 30, 2021 | -208.18M |
| March 31, 2021 | -183.02M |
| December 31, 2020 | -165.37M |
| September 30, 2020 | -64.50M |
| June 30, 2020 | -62.21M |
| March 31, 2020 | -65.19M |
| December 31, 2019 | -86.43M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-7.529B
Minimum
Dec 2023
6.505M
Maximum
Sep 2022
-1.172B
Average
-208.18M
Median
Jun 2021
Cash from Investing (TTM) Benchmarks
| Pfizer Inc | -32.28B |
| BioVie Inc | 0.2239M |
| Autolus Therapeutics PLC | -10.99M |
| Moderna Inc | 4.206B |
| Novavax Inc | -58.81M |